Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Day 100 Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cell Receptors Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas

Luis Porrata, Stephen M Ansell, Ivana Micallef, Patrick B Johnston, J. C. C Villasboas, Jonas Paludo, Urshila Durani, Svetomir Markovic

Blood (2023) 142 (Supplement 1): 4967.

https://doi.org/10.1182/blood-2023-173453

Published: 2023

Journal Articles

A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report

Thomas M. Habermann, Betsy LaPlant, Ivana Micallef, Heidi Diann Finnes, Jill Schimke, Robin Klebig, Nikki Hanley, Rebecca L. King, Thomas E. Witzig, Svetomir Markovic

Blood (2023) 142 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2023-175014

Published: 2023

Journal Articles

Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas

Luis Porrata, MD, David J Inwards, MD, Stephen M. Ansell, MD PhD, Ivana N Micallef, MD, Patrick Johnston, Jose C Villasboas, William J. Hogan, MBBCh, Svetomir Markovic, MD PhD

Blood (2018) 132 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2018-99-109922

Published: 2018

Journal Articles

Sustained Natural Killer Cell Recovery Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Non-Hodgkin's Lymphoma

Luis Porrata, MD, David James Inwards, MD, Stephen M Ansell, MD, PhD, Ivana Micallef, MD, Patrick B. Johnston, MD PhD, Wendy Nevala, Svetomir Markovic, MD PhD

Blood (2016) 128 (22): 4641.

https://doi.org/10.1182/blood.V128.22.4641.4641

Published: 2016

Journal Articles

Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma

Luis Porrata, MD, Kay Ristow, Ellen D. McPhail, MD, William Macon, MD, Matthew J Maurer, MS, Grzegorz S. Nowakowski, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD, Svetomir Markovic, MD PhD, Thomas M. Habermann, MD

Blood (2015) 126 (23): 3885.

https://doi.org/10.1182/blood.V126.23.3885.3885

Published: 2015

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience

Grzegorz S. Nowakowski, MD, Kay Ristow, Paul Kurtin, MD, Mark S Allen, Ivana N Micallef, MD, Joseph Colgan, David James Inwards, MD, Ellen McPhail, MD, Svetomir Markovic, MD, PhD, Stephen M. Ansell, MD, PhD, Luis Porrata, MD, Patrick B Johnston, MD, PhD, Carrie A Thompson, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD

Blood (2010) 116 (21): 4168.

https://doi.org/10.1182/blood.V116.21.4168.4168

Published: 2010

Journal Articles

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

Matthew J Maurer, James Cerhan, MD, PhD, Jerry A Katzmann, PhD, Brian Link, Ivana N Micallef, MD, Joseph Colgan, MD, Thomas M. Habermann, MD, David James Inwards, MD, Svetomir Markovic, MD, PhD, Stephen M. Ansell, MD, PhD, Luis Porrata, MD, Patrick B Johnston, MD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Mamta Gupta, Ph.D, Sergei I Syrbu, MD, Paul Kurtin, MD, William Macon, MD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 4136.

https://doi.org/10.1182/blood.V116.21.4136.4136

Published: 2010

Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Blood (2010) 116 (21): 287.

https://doi.org/10.1182/blood.V116.21.287.287

Published: 2010

Journal Articles

The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma

Ryan A. Wilcox, MD, PhD, Kay Ristow, Thomas M. Habermann, MD, David James Inwards, MD, Ivana Micallef, MD, Patrick B Johnston, MD, PhD, Joseph Colgan, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD, Svetomir Markovic, MD, PhD, Luis Porrata, MD

Blood (2010) 116 (21): 3088.

https://doi.org/10.1182/blood.V116.21.3088.3088

Published: 2010

Journal Articles

Absolute Lymphocyte Count Assessed During Routine Follow-up Is a Risk Factor for Relapse Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma.

Luis Porrata, MD, David J Inwards, Stephen M Ansell, Ivana Micallef, Patrick L Johnston, MD, PhD, William Hogan, MD, Svetomir Markovic

Blood (2009) 114 (22): 4359.

https://doi.org/10.1182/blood.V114.22.4359.4359

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Craig B. Reeder, MD, Michel K. Gornet, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Ivana N. Micallef, MD, Luis F. Porrata, MD, Patrick B. Johnston, MD, PhD, Matthew J. Maurer, MS, Betsy LaPlant, MS, Brian Kabat, MS, David J. Inwards, MD, Joseph P. Colgan, MD, Timothy Call, MD, Svetomir Markovic, MD, PhD, Clive S. Zent, MD, Steven R. Zeldenrust, MD, PhD, Han W. Tun, MD, Thomas E. Witzig, MD

Blood (2007) 110 (11): 121.

https://doi.org/10.1182/blood.V110.11.121.121

Published: 2007

Journal Articles

Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.

Deepti Behl, MD, Kay M. Ristow, RN, Svetomir Markovic, MD, PhD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Joseph P. Colgan, MD, Ivana N.M. Micallef, MD, Patrick B. Johnston, MD, PhD, Stephen Ansell, MD, PhD, Christopher A. Yasenchak, MD, Rajnish Manchanda, MBBS, Luis F. Porrata, MD

Blood (2006) 108 (11): 3878.

https://doi.org/10.1182/blood.V108.11.3878.3878

Published: 2006

NARROW

Day 100 Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cell Receptors Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas

A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report

Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas

Sustained Natural Killer Cell Recovery Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Non-Hodgkin's Lymphoma

Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma

Absolute Lymphocyte Count Assessed During Routine Follow-up Is a Risk Factor for Relapse Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only